Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at up-to-date safety data on Leqembi (lecanemab) at its next meeting in ...

Leqembi (lecanemab-irmb) is a brand-name drug prescribed to treat Alzheimer’s disease in adults with mild cognitive impairment or mild dementia. The drug comes as an intravenous (IV) infusion ...

Biogen has given an update on the rollout of its Eisai-partnered Alzheimer’s disease therapy Leqembi alongside its ... according to data from a registry run by the Centers for Medicare ...

The milestone was reached as sales of Leqembi reached €200 million in Eisai fiscal year 2024 (April 2024 - Match 2025). The event entitles BioArctic to a €10 million payment. Leqembi is the ...

Investing.com -- Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai's robust sales figures for Leqembi, which exceeded consensus estimates.

The company anticipates continued growth for LEQEMBI, supported by upcoming regulatory milestones, including a subcutaneous formulation for maintenance (PDUFA date: August 31, 2025) and ...

NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on Friday ...